NewsBenzingaBristol Myers Squibb presenta i risultati a 56 settimane dello studio clinico di fase 3 SCOUT-HCM in una presentazione late-breaker alle sessioni scientifiche dell’HCMS Bristol Myers Squibb presenta i risultati a 56 settimane dello studio clinico di fase 3 SCOUT-HCM in una presentazione late-breaker alle sessioni scientifiche dell’HCMS Benzinga 2026.11.06 21:01 (GMT+0) Open on Benzinga Other news David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Bernstein Maintains Market Perform on Tyson Foods, Raises Price Target to $72 Broadcom Stock Is Up Tuesday: AI Chip Diversification, Dec. 9 Earnings, Analyst Targets Bernstein Downgrades PepsiCo to Underperform, Lowers Price Target to $128 If You Invested $1000 In Humana Stock 20 Years Ago, You Would Have This Much Today What's Going On With Ouster Stock Tuesday?